Peters, L;
Cozzi-Lepri, A;
Hepatitis C Working Group for the Collaboration of Observational, .;
(2016)
Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Positive Patients?
AIDS
, 31
(5)
pp. 661-668.
10.1097/QAD.0000000000001378.
Preview |
Text
Cozzi-Lepri_00002030-900000000-97592.pdf Download (808kB) | Preview |
Abstract
BACKGROUND: Long-term clinical outcomes after HCV treatment of HIV/HCV patients are not well described. We aimed to compare the risk of all-cause and liver-related death according to HCV treatment response in HIV/HCV patients in the multi-cohort study COHERE. METHODS: All patients who had started PEG-interferon + ribavirin (baseline) and followed for ≥72 weeks after baseline were included. Patients were categorized into three response groups depending on treatment duration and HCV-RNA measured in the window 24-72 weeks after baseline. Patients who received ≥24 weeks of therapy were defined as responders if their last HCV-RNA measured between 24-72 weeks after baseline was negative, and having "unknown response" if HCV-RNA was unknown. Non-responders were treated for less than 24 weeks or were HCV-RNA+ between 24-72 weeks after baseline.Mortality rates were compared using survival analysis, and Cox regression used to compare hazard ratios of death between response groups. RESULTS: 3,755 patients were included: 1031 (27.5%) responders, 1,639 (43.6%) non-responders and 1085 (28.9%) with unknown response. Rates (per 1,000 PYFU, 95% CI) of all-cause death were 17.59 (14.88-20.78), 10.43 (7.62-14.28) and 11.00 (8.54-14.23) for non-responders, responders and unknown responders, respectively. After adjustment, the relative hazard (non-responders vs. responders) for all-cause death, liver-related death and non-liver-related death was 1.53 (95% CI 1.06-2.22), 3.39 (95% CI 1.32-8.75) and 1.22 (95% CI 0.80-1.84), respectively. CONCLUSION: HIV/HCV patients with a favourable virological response to PEG-interferon + ribavirin had reduced risk of all-cause and liver-related death, while there was no difference in risk of non-liver-related death when comparing responders and non-responders.
| Type: | Article |
|---|---|
| Title: | Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Positive Patients? |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1097/QAD.0000000000001378 |
| Publisher version: | http://dx.doi.org/10.1097/QAD.0000000000001378 |
| Language: | English |
| Additional information: | Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. This is a non-final version of an article published in final form in Peters, L; Cozzi-Lepri, A; Hepatitis C Working Group for the Collaboration of Observational; (2016) Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Positive Patients? AIDS 10.1097/QAD.0000000000001378 |
| Keywords: | HIV; HEPATITIS C; HCV; MORTALITY; INTERFERON; RIBAVIRIN |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health > Infection and Population Health |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1534365 |
Archive Staff Only
 |
View Item |
